Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ12220,41
KB-1,06
PKN88,1488,171,43
Msft-0,06
Nokia4,234,280,38
IBM0,07
Mercedes-Benz Group AG51,9651,98-2,43
PFE-1,17
14.07.2025 22:15:00
Indexy online
AD Index online
select
AD Index online
 

  • 14.07.2025 15:38:04
Eisai (ESALF.PK, US Other OTC (Pink Sheets))
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
29,44 -0,77 27,14 50
After-hours14.07.2025 15:38:04
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
29,44 - - -0,77 27,14
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.07.2025
Popis společnosti
Obecné informace
Název společnostiEisai Co Ltd
Ticker4523
Kmenové akcie:Ordinary Shares
RIC4523.T
ISINJP3160400002
Poslední známé roční výsledky31.03.2025
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.03.2025 13 506
Akcie v oběhu k 31.03.2025 282 115 900
MěnaJPY
Kontaktní informace
UliceEisai Main Bldg., 4-6-10, Koishikawa
MěstoBUNKYO-KU
PSČ112-8088
ZeměJapan
Kontatní osobaShinichi Sagawa
Funkce kontaktní osobyDirector of Accounting in Main Finance & Accounting Unit
Telefon81 338 173 700
Fax81338113305
Kontatní telefon810 338 173 030

Business Summary: Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Financial Summary: BRIEF: For the fiscal year ended 31 March 2025, Eisai Co Ltd revenues increased 6% to Y789.4B. Net income increased 9% to Y46.43B. Revenues reflect Pharmaceutical Business segment increase of 8% to Y749.03B, America segment increase of 13% to Y286.58B, China segment increase of 17% to Y127.49B, Others segment increase of 17% to Y72.31B. Net income benefited from Pharmaceutical Business segment income increase of 2% to Y350.5B.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Process, Phys Dist & Log Consulting Services
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Process, Physical, Distribution and Logistics Consulting Services
SICPharmaceutical Preparations



  • Poslední aktualizace: 14.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Representative Executive Officer, DirectorHaruo Naito77
Executive Officer, Chief Financial Officer, Chief Director of Finance and AccountingMitsuru Shomon5310.07.202301.04.2023
Senior Managing Executive Officer, Representative Executive Officer, Chief Operating Officer, Chief Growth Officer, CEO of SubsiKeisuke Naito3614.06.2024
Executive Officer, Chief Human Resources OfficerTeruyuki Masaka47
Executive Officer, Chief Information Officer, Chief Director of Global Digital Business ReformMakoto Hoketsu5601.04.2025
Executive Officer, Chief Scientific OfficerKatsutoshi Ido4601.04.202501.04.2025
Executive Officer, Chief Compliance Officer, Director of Legal AffairsShin Kato5314.06.202414.06.2024
Senior Managing Executive Officer, Chief Business Officer, Chief IR Officer, Representative Executive OfficerTerushige Iike6101.04.2025
Managing Executive Officer, President of SubsidiaryYanhui Feng5214.06.2024
Managing Executive Officer, President of EMEA Region, Chairman & Chief Executive Officer of SubsidiaryGary Hendler58